4F-MDMB-BINACA, also recognized as 4F-MDMB-BUTINACA or 4F-ADB, belongs to the indazole-3-carboxamide family, making it an indazole-based synthetic cannabinoid. It has been prevalent as an active component in synthetic cannabis products and has been accessible as a designer drug since late 2018. 4F-MDMB-BINACA acts as an agonist of the CB1 receptor (with an EC50 of 7.39 nM), but its selectivity for this specific target remains uncertain. Notably, in December 2019, the United Nations Office on Drugs and Crime (UNODC) introduced scheduling recommendations, proposing the classification of 4F-MDMB-BINACA as a Schedule II substance on a global scale.
|Chemical and physical data|
|Molar mass||363.433 g·mol−1|
A related compound, 4F-MDMB-BICA (4F-MDMB-BUTICA), featuring an analogous indole core, emerged as a designer drug in May 2020 and gained popularity through online chemical suppliers.
Under the Psychoactive Substances Act 2016, it is illegal to engage in the sale, distribution, supply, transportation, or trade of this pharmaceutical drug.
The DEA has issued a notice of intent to temporarily designate 4F-MDMB-BUTICA (not including 4F-MDMB-BINACA itself) as a Schedule I substance. This designation is set to commence on or after May 4, 2023, with a potential duration of up to 2 years. During this period, the DEA may pursue permanent scheduling. Should no such filing occur by May 4, 2025, the temporary Schedule I classification will lapse.
Additionally, North Dakota officially classified 4F-MDMB-BINACA as a Schedule I substance on April 27, 2023.
- What is 4F-MDMB-BINACA?
- 4F-MDMB-BINACA is an indazole-based synthetic cannabinoid, often used as an active ingredient in synthetic cannabis products or designer drugs.
- How is 4F-MDMB-BINACA classified in the United Kingdom?
- In the United Kingdom, 4F-MDMB-BINACA is considered illegal under the Psychoactive Substances Act 2016. This means it cannot be sold, distributed, supplied, transported, or traded.
- What is the classification of 4F-MDMB-BUTICA in the United States?
- In the United States, the Drug Enforcement Administration (DEA) has issued a notice of intent to temporarily place 4F-MDMB-BUTICA (not 4F-MDMB-BINACA) into Schedule I status. This designation may begin on or after May 4, 2023, with a potential 2-year duration. The DEA may also seek permanent scheduling during this period.
- What are the implications of the temporary Schedule I status in the United States?
- The temporary Schedule I status for 4F-MDMB-BUTICA, if implemented on May 4, 2023, will last until May 4, 2025. If the DEA does not proceed with permanent scheduling within these two years, the temporary classification will expire.
- When was 4F-MDMB-BINACA placed into Schedule I in North Dakota?
- North Dakota officially classified 4F-MDMB-BINACA as a Schedule I substance on April 27, 2023.
- Is 4F-MDMB-BINACA safe for consumption?
- The safety of 4F-MDMB-BINACA is a subject of concern, as it is often found in unregulated designer drugs. The effects and risks associated with its use are not well-documented, and its consumption may have unpredictable and potentially harmful consequences.
- What are the potential legal consequences of possessing or distributing 4F-MDMB-BINACA in the United States?
- In the United States, possessing, distributing, or dealing with 4F-MDMB-BINACA may lead to legal repercussions, as it could be classified as a controlled substance. Legal consequences can include fines and imprisonment.
- Is 4F-MDMB-BINACA the same as 4F-MDMB-BUTICA?
- No, 4F-MDMB-BINACA and 4F-MDMB-BUTICA are distinct compounds, albeit related. Their legal classifications and regulations may differ, so it is important to be aware of these differences when dealing with these substances.
- Anvisa’s Resolution: On July 24, 2023, Anvisa issued a resolution known as “RDC Nº 804.” This resolution, published in the Diário Oficial da União on July 25, 2023, pertains to lists of narcotic, psychotropic, precursor, and other substances under special control in Brazilian Portuguese. It was archived from the original source on August 27, 2023.
- Forensic Implications: In September 2019, a study published in the “Journal of Forensic Sciences” shed light on the synthetic cannabinoid 4F-MDMB-BINACA, which has been widely implicated in forensic casework. This study delved into the implications of this synthetic cannabinoid in forensic investigations.
- Fatal Intoxication Investigation: In December 2022, a study published in “Forensic Science, Medicine, and Pathology” explored a fatal intoxication case involving new synthetic cannabinoids, 5F-MDMB-PICA and 4F-MDMB-BINACA. The study focused on the identification of parent compounds and metabolites in blood, urine, and cerebrospinal fluid.
- Toxicokinetics Research: Research in October 2022, published in the “Archives of Toxicology,” delved into the toxicokinetics of synthetic cannabinoids. This study specifically investigated the in vitro contribution of human carboxylesterases to the toxicokinetics of these substances.
- Synthetic Cannabinoid Synthesis: In December 2020, a study published in “ACS Chemical Neuroscience” discussed the synthesis and in vitro cannabinoid receptor 1 activity of recently detected synthetic cannabinoids, including 4F-MDMB-BINACA. This research provided insights into the activity of various synthetic cannabinoids.
- Chemical Information: For further reference, a document titled “4F-MDMB-BINACA(4F-MDMB-BUTINACA)” in PDF format is available. This document likely contains valuable chemical information about 4F-MDMB-BINACA.
- WHO Scheduling Recommendations: In December 2019, the World Health Organization (WHO) recommended the scheduling of 12 new psychoactive substances (NPS), possibly including 4F-MDMB-BINACA. This indicates the global concern regarding the scheduling of such substances.
- Analytical Data: The Hungarian Institute for Forensic Sciences has published analytical data for 4F-MDMB-BICA, a compound closely related to 4F-MDMB-BINACA. This data might offer insights into the analysis of synthetic cannabinoids.
- Scheduling in the United States: On April 4, 2023, the United States Federal Register included a notice regarding the temporary placement of several synthetic cannabinoids, including 4F-MDMB-BUTICA. This temporary placement involves scheduling these substances under federal law.
- North Dakota Legislation: In North Dakota, an act was passed on January 3, 2023, related to the scheduling of controlled substances. This legislation could affect the legal status of synthetic cannabinoids like 4F-MDMB-BINACA within the state.